Concert Pharmaceuticals, Inc. Presents Preclinical Results Demonstrating CTP-499, a Novel Treatment for Diabetic Kidney Disease, Ameliorated Renal Fibrosis and Inflammation In Vivo
11/2/2012 9:02:42 AM
SAN DIEGO--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today presented preclinical results which demonstrated CTP-499’s anti-fibrotic and anti-inflammatory properties in vivo. These findings were presented in a poster at the American Society of Nephrology’s (ASN) Kidney Week 2012. CTP-499 is currently in Phase 2 clinical development in patients with diabetic nephropathy, the leading cause of chronic kidney disease (CKD) worldwide.
comments powered by